Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 172Esophageal Neoplasms 161Esophageal Squamous Cell Carcinoma 116Cholangiocarcinoma 77Pancreatic Neoplasms 73Biliary Tract Neoplasms 72Adenocarcinoma Of Esophagus 52Gallbladder Neoplasms 39Colorectal Neoplasms 36Neoplasm Metastasis 30Carcinoma, Non-Small-Cell Lung 28Carcinoma, Hepatocellular 28Neoplasms 27Bile Duct Neoplasms 24Ovarian Neoplasms 19Liver Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 15Colonic Neoplasms 13Peritoneal Neoplasms 12Gastrointestinal Neoplasms 12Anus Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Adenocarcinoma 11Rectal Neoplasms 9Melanoma 9Lung Neoplasms 9Carcinoma, Squamous Cell 9Breast Neoplasms 9Sarcoma 8Hepatoblastoma 8

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Biliary Tract Cancer × Cisplatin × Gastrointestinal × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡